Keeping Biopharma’s Essential Services Lifeline Afloat During COVID
Subrata Chakraborty, GxPFONT Consulting Group

Whoever penned the term “essential services” should have included packaging material manufacturers, laboratory glassware suppliers, HVAC project engineers, and calibration service providers in the list. The lives of patients around the world depend as much on the continuity of operations of these supporting industries as they do on drug manufacturers.

When COVID-19 hit, many of these companies kept operations working with the help of remote access to the machines and other technology. Machine service engineers located overseas guided local service support online to help solve problems.

The most challenging questions that this industry had to quickly answer were:
1. How do you set up an imported machine that needs technical support from the Original Equipment Manufacturer (OEM) with restrictions on international travels?
2. How do you fix your most complex machine problems when they require a manufacturer’s intervention?
3. Can you continue the smooth operations of production, R&D, or a QC laboratory with a broken-down supply chain of regular consumables?

The following case studies examine the challenges that the supporting industries unexpectedly faced and how they were overcome.

**SCENARIO 1**

**Milieu:** Pharmaceutical manufacturers, especially the ones racing to develop a vaccine for COVID-19, were in dire need of local as well as overseas engineers to complete the final stages of operational commissioning to enable production.

**Challenges faced:** It was to be a leap of faith, because time was the biggest challenge and synchronization of all actions from all quarters was a prerequisite. Having tests for COVID-19 performed, being issued test certificates, gathering tickets and travel gear and observing all the protocols for flying were indeed challenging, but not impossible.

**Actions taken:** Thanks to the network of contacts of these essential services industries, companies mobilized their resources to support their cause and ensure that the engineers were put on the “Vande Bharat Flights” (special flights to repatriate the overseas workmen). Armed with special permissions and express visas to arrive in time for the activities, all clearances and arrangements were made for their smooth transit into and out of the country. Precautions were taken for the assignment at hand, the well-being of teams from every angle was of the highest order.

**Lessons learned:** Travelling is a basic venture taken for granted, and business requirements necessitates it when subject matter experts are required to be on customer sites to erect, commission, repair or pull down the system or equipment. With the rules of quarantine in place, viability of travel and access to solving problems takes longer and costs escalate. The need to establish case- or person-specific quarantine rules instead of a general one-size-fits-all rule emerged.

Continued on page 11
The 2021 PDA Annual Meeting promises to have something for everyone. Dive into exciting interactive sessions and tracks especially designed for early career professionals, manufacturing leaders, and technical experts/scientists, all offered in a fully digital format for easy access from anywhere in the world.

No matter what your area of focus, you are sure to come away with tangible, practical solutions to improve your operations and your standing within your company!

Stay tuned for more information on the intriguing lineup of sessions, speakers, and networking activities.

Register early to take advantage of the most significant discounts!

For more information and to register, visit pda.org/2021annual
Keeping Biopharma’s Essential Services Lifeline Afloat During COVID

Voices of PDA

5 Roller Coaster Year Comes to an End

News & Notes

6 2021 BOD and Officers

Manufacturing Science

9 PDA Education Offered 18 Online Courses to Members in Asia-Pacific and India in 2020

12 Chemical Durability Ratio: Method Provides Leading Indicator of Delamination Risk

Biopharmaceuticals and Biotechnology

14 T-Cell Therapy Saves a Life

Supply Chain & Outsourcing

16 PDA President Richard Johnson on the Impact of COVID-19 on the Supply Chain
Are you curious about the issues unique to your region?

Another layer of PDA leadership resides at the grassroots level in the Chapter organizations. Regional PDA Chapters provide local services to the membership, including translations of PDA publications, networking social events, student scholarship and annual regulatory and technical conferences. Each Chapter is managed by volunteer leaders.

Learn more about your local Chapter at pda.org/Chapters
Roller Coaster Year Comes to an End

I can say without any reservation that 2020, has been a roller coaster year for the industry, starting with the interruptions of the PPE supply to creating a safe working environment for employees to redesigning supply and logistics networks in a rapidly changing environment. It has been a dramatic year in which many made leaps into the digital age, much faster than anyone would have considered making during a “normal” year. But as resilience kicked in, pharma has adapted to new ways and processes and retained output and control. Inspections became virtual, and new processes, procedures and technologies were created.

At PDA, we created the COVID-19 Task Force that developed recommendations for the industry. There are some interesting podcast to explore in the website https://www.pda.org/news/pda-coronavirus-updates

Our 2020 plan consisted of visiting various countries and participating as thought leaders in various events in the region. Obviously the plan needed to be changed and adapted. Instead, we focussed on moving into digital learning, which became quickly a crowded space. PDA remained active with the members and continues to release new reports and books, and provided much of the e-learning on demand. [Editor’s Note: See a full list of PDA Education’s Asia Pacific offerings for 2020 on page 9.]

For 2021 you can expect this to continue. The Asia Pacific Office will work with local advisory committees to create events with content relevant to them, and these committees will recommend what content they’d like to include from the U.S. and EU Meetings. In short, we will bring the meetings to you in a way that suits you. Yes, this will be mainly digital but we remain committed to launch in-person events in the latter half of 2021 should the world slowly return to business travel. We will see what this will bring.

We remain committed to supporting our Chapters in the region, and will continue to offer them way to enable a better and more effective way for their activities and streamline this at the same time with PDA programs.

Finally, I would like to request for your ideas and suggestions on what you think we should be focussing on in 2021 in addition to our current plans. Kindly email me at ewals@pda.org.

The Asia-Pacific team wishes everyone a great 2021 ahead.
2021 BOD and Officers

Chair
Jette Christensen, PhD
Novo Nordisk

Chair-Elect
Sue Schniepp
RCA

Treasurer
Melissa Seymour
Biogen

Secretary
Emma Rammarine
Genentech/Roche

Immediate Past Chair
Rebecca Devine, PhD
Regulatory Consultant

Barbara M. Allen, PhD
Eli Lilly

Michael Blackton
Adaptimmune

Bettine Boltres, PhD
West Pharmaceutical Services

Tia Bush
Amgen

Javier Camposano
Celltrion

Ghada Haddad
Merck & Co.

Joyce Hansen
Johnson & Johnson

Stephan Krause, PhD
AstraZeneca Biologics

Mary Oates, PhD
Pfizer

Mathias Romacker
Pfizer (ret.)

Anil Sawant, PhD
Merck & Co., Inc

Osamu Shirotizawa
LifeScientia

PDA News

Onsite Training
Customized, Convenient, and Cost Effective

PDA can design, develop, and deliver custom training course content, drawing from our extensive network of subject matter experts. We provide:

• Practical knowledge and skills that improve job performance in a range of important topics
• Engaging instructors with years of industry and agency experience
• The highest quality training, where you want it, when you want it, and at a competitive price

Let us help you succeed with custom solutions and training at your facility or at ours!

Email info@pda.org to get started today.

pda.org/onsite
SAVE THE DATE
for the 2021 Line-up of Conferences

Plan ahead for a year filled with best-in-class content and experiences from PDA. We’ll be starting the year mostly online, delivering flexible, accessible, and engaging events. We are optimistically planning to come back together in person in the second half of the year, while continuing to offer a virtual component to these events for those who are still unable to travel. The best of both worlds!

2021 PDA Annual Meeting
15-17 MARCH
Presented Virtually
pda.org/2021annual

2021 PDA Visual Inspection Forum
14-15 APRIL
Presented Virtually
pda.org/2021visual

2021 PDA Parenteral Packaging Conference
27-28 APRIL
Basel, Switzerland and Online
pda.org/eu/2021parpack

2021 PDA Pharmaceutical Microbiology Conference
4-6 OCT.
Washington, DC and Online
pda.org/2021micro

2021 PDA Universe of Pre-Filled Syringes and Injection Devices Conference
5-6 OCT.
Gothenburg, Sweden and Online
pda.org/eu/2021ups

Visit pda.org/calendar for the global calendar of events!
2021 PDA
THE UNIVERSE OF PRE-FILLED SYRINGES AND INJECTION DEVICES CONFERENCE

5-6 OCTOBER 2021
GOTHENBURG, SWEDEN
WORKSHOPS: 4 OCT
CONFERENCE & EXHIBITION: 5-6 OCT
TRAINING: 7-8 OCT
PDA Education Offered 18 Online Courses to Members in Asia-Pacific and India in 2020

The COVID-19 pandemic hardly slowed down PDA Education. The group used online tools to offer 18 courses to PDA members in the Asia-Pacific region and India.

<table>
<thead>
<tr>
<th>Course Code</th>
<th>Title</th>
<th>Region</th>
<th>Subject</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDA 737</td>
<td>Terminal Heat Sterilization</td>
<td>Online – India</td>
<td>Sterilization</td>
<td>04/28/20</td>
</tr>
<tr>
<td>PDA 712</td>
<td>Aseptic Processing – Cleanroom Behavior, Health &amp; Hygiene</td>
<td>Online – India</td>
<td>Aseptic Processing</td>
<td>06/15/20</td>
</tr>
<tr>
<td>PDA 735</td>
<td>Container Closure Integrity Testing</td>
<td>Online – APAC</td>
<td>Parenteral Packaging</td>
<td>06/23/20</td>
</tr>
<tr>
<td>PDA 734</td>
<td>Cleaning and Disinfection</td>
<td>Online – APAC</td>
<td>Cleaning</td>
<td>06/25/20</td>
</tr>
<tr>
<td>PDA 598</td>
<td>Regulatory Inspections</td>
<td>Online – India</td>
<td>Quality Assurance</td>
<td>07/07/20</td>
</tr>
<tr>
<td>PDA 730</td>
<td>Isolator Technology</td>
<td>Online – India</td>
<td>Aseptic Processing</td>
<td>07/14/20</td>
</tr>
<tr>
<td>PDA 247.2</td>
<td>Technical Report No. 70: Fundamentals of Cleaning and Disinfection Programs for Aseptic Manufacturing Facilities</td>
<td>Online – APAC</td>
<td>Cleaning</td>
<td>07/15/20</td>
</tr>
<tr>
<td>PDA 619</td>
<td>Visual Inspection – India</td>
<td>Online – India</td>
<td>Visual Inspection</td>
<td>08/11/20</td>
</tr>
<tr>
<td>PDA 732</td>
<td>Filtration</td>
<td>Online – India</td>
<td>Filtration</td>
<td>08/18/20</td>
</tr>
<tr>
<td>PDA 735</td>
<td>Container Closure Integrity Testing</td>
<td>Online – India</td>
<td>Parenteral Packaging</td>
<td>09/29/20</td>
</tr>
<tr>
<td>PDA 853.1</td>
<td>Environmental Monitoring</td>
<td>Online – India</td>
<td>Environmental Monitoring</td>
<td>10/06/20</td>
</tr>
<tr>
<td>PDA 724</td>
<td>Aseptic Processing - Gowning, Qualification, Requalification</td>
<td>Online – India</td>
<td>Aseptic Processing</td>
<td>10/19/20</td>
</tr>
<tr>
<td>PDA 712</td>
<td>Aseptic Processing - Cleanroom Behavior, Health &amp; Hygiene</td>
<td>Online – India</td>
<td>Aseptic Processing</td>
<td>11/30/20</td>
</tr>
<tr>
<td>PDA 853.1</td>
<td>Environmental Monitoring</td>
<td>Online – APAC</td>
<td>Environmental Monitoring</td>
<td>12/01/20</td>
</tr>
<tr>
<td>PDA 247.2</td>
<td>Technical Report No. 70: Fundamentals of Cleaning and Disinfection Programs for Aseptic Manufacturing Facilities</td>
<td>Online – India</td>
<td>Cleaning</td>
<td>12/08/20</td>
</tr>
<tr>
<td>PDA 726</td>
<td>Aseptic Processing - Facilities</td>
<td>Online – India</td>
<td>Aseptic Processing</td>
<td>12/15/20</td>
</tr>
</tbody>
</table>
The basic lesson learned is that, with due logic and applying common sense in the situation, workable solutions can be identified, planned and implemented. This pandemic is not going to end soon, and industry will have to fine tune its modus operandi to circumvent the hurdles accordingly.

**SCENARIO 2**

**Milieu:** The challenges faced by the regular manufacturing and laboratory consumable suppliers due to continued lockdowns in the country are related to on-time delivery of their products and services to the customers in pharmaceutical and biotech industry. Even after relaxation of the lockdown norms now, they continued to face challenges to serve customers due to sudden lockdowns or restrictions that are imposed by the local municipal authorities.

Paramjyoti Chakraborty, country head of BRAND Scientific Equipment, a leading laboratory instruments and consumables supplier in India, says:

“We are very much affected due to the lockdown norms. This has resulted in a cost escalation of around 25% in logistics apart from the increased cost of imports due to unavailability of passenger airlines helping in small cargo movements. So, for our products that qualify as premium products, especially for the pharmaceutical R&D and QC laboratories, we are left to bear this additional cost as a burden. Further, with limited cargo options on the international circuit, we are also forced to build up our inventories, since our customers working on various life-saving products can’t keep waiting for our products.”

**Challenges faced:** On-time delivery of the products and services at customer sites was most crucial. Due to various uncertainties, such vendors did not have enough time to plan their orders: either they received a sudden spike in demand, or they had inventories that remained on their shelves for weeks because of no demand.

“The transportation of instruments to the customer sites were nerve-wracking experiences due to the disruptions in supply chain and logistics services,” says Chakraborty.

**Actions taken:** The key actions involved increasing inventory-carrying norms, focusing on effectiveness of supply chain and introducing innovative approaches towards after-market services like product training and product service support, mostly through virtual means with limited physical presence by local resources.

Chakraborty explained, “To stay connected with our customers for our support, we are available on almost all online platforms based on customers’ choice. We have created product application videos for our customers that we use during the online meetings to demonstrate our products and we also provide virtual runs for some of our high-end products with inputs from our customers to their application requirements.

“On the internal side, we have updated our systems and continuously train all our team members with knowledge updates to deal with this changed scenario so that they can efficiently and seamlessly work with their customers, service providers and vendors.”

**Lessons learned:** The learning comes every hour and every day. Business agility with people, and the ability to shift gears with processes, is what will help sustain this industry in the post-COVID era.

**Where do we go from here?**

The next few quarters could remain as challenging as it has been for all ancillary businesses related to the biopharmaceutical and pharmaceutical industries, with shortages of the workforce, the uncertainty of demand, and the increasing cost of operations.

To maneuver through these choppy waters, first the business leaders of these industries must build better visibility of their entire system. This will come from adopting advanced technologies and digitizing their operations and supply chain networks. Next, efficiency in operations must be strengthened to meet the changing needs of the business and yet remain competitive. This would also call for building more of a regionalized structure than a global structure, investing in local talents, and ensuring the overall adaptability to these new business norms. The success of this entire ecosystem will depend upon the ability to co-create a business environment that will move towards a new patient-centric business model. Figure 1 depicts the path forward for ancillary industries.

**Conclusion**

Indeed, these are turbulent times, but the bright side is the innate adaptability and resilience that businesses in the essential services have displayed to make things work.

**About the Author**

Subrata Chakraborty volunteers for the PDA Letter Editorial Committee for Asia Pacific region. He leads the GxPFONT Consulting Group as Principal Advisor and has over 24 years of experience in handling pharmaceutical manufacturing and quality operations in various capacities with subject matter expertise in Aseptic Technology.
Chemical Durability Ratio: Method Provides Leading Indicator of Delamination Risk

Robert Schaut, Kelly Murphy (formerly), Daniel Kramer, Christy Chapman, and Carol Rea Flynn, Corning Inc.

Glass delamination has been at the forefront of the pharmaceutical industry since the FDA published its advisory in 2011.

The term delamination refers to the production of thin, visible, glassy particles in a drug product following a corrosion process. Formation of delamination particles has been linked to heterogeneous (non-uniform) surface chemistry in the heel area of the glass vial generated during the tube-to-container converting process. An improved approach to assessing delamination risk based on the degree of non-uniform surface chemistry is recommended. Benefits of this method will be compared to existing screening strategies that rely upon lagging indicators and lamellae generation.

While chemical characterization techniques (DSIMS, XPS and SEM) are well-suited to evaluate changes in surface chemistry that have been linked to delamination, they have limitations, including: high cost, significant analysis time/technical training, influence of sample preparation and small area investigated (less than 1 mm² on one part). Current delamination testing methods, such as USP <1660> Evaluation of the Inner Surface Durability of Glass Containers, are also not sufficient for a definitive determination of delamination risk. These methods rely upon observation of glass lamellae, which frequently do not occur within the recommended testing timescales but could appear later or be dissolved due to aggressive test conditions. Also, some methods (such as those described in USP <1660>) lack prescriptive detail, leading to differences in test methods (from lab to lab) and qualitative, noncomparable results. This new method, chemical durability ratio (CDR), characterizes the degradation of chemical durability due to surface heterogeneities present in some pharmaceutical glass containers. It is intended to complement the compendial USP <660> Surface Glass Test and applies to containers that already meet Type I performance criteria.

As pictured in Figure 1, the method consists of:
1. A hydrolytic test of the “as-received” surface
2. An etching step to remove any chemical heterogeneities that may be present
3. A second hydrolytic test of the “etched” surface

“As-received” containers are processed according to USP <660>, with one notable deviation: the filling volume is 12.5% of the brimful capacity. The low filling volume is used to focus on the glass surface area that would be in contact with drug solution and that exhibits degraded durability, e.g., heel area. The titration volume is recorded as the “as-received” response.

A second surface glass test is conducted on “etched” containers to measure the bulk glass response, again at the reduced 12.5% filling volume. The etching process removes the material deposited or incorporated during the converting or molding process. At least one micron (depth) of the surface is removed using a mixture of hydrofluoric and hydrochloride acids, with target concentrations of 2.3 M HF/4.6 M HCl. The containers are exposed to this solution for a minimum of three minutes. These conditions are sufficient for most glass compositions, and the mass lost is measured to confirm sufficient depth of surface removal. After exposure to the target acid solution, acidic residue in the containers is removed through soaking in two room temperature water baths for five minutes each. Subsequently, the containers are rinsed with high-purity water several times. Containers used for the “etched” response can either be a completely unique set or the retained containers from the “as-received” test. The “etched” containers are processed according to USP <660>, using the reduced fill volume (12.5% of the brimful capacity). The resulting titrant volume is recorded as the “etched” titrant response.

A ratio of the recorded titrant volumes, as illustrated in Figure 2, provides a measure of the level of surface heterogeneity.

Containers with uniform surface chemistry have the lowest risk of delaminating, and they exhibit CDR ratios between -0.5 and -2.0. Containers converted with care to produce minor heterogeneities will have CDR ratios between -2.0 and -5.0. While lower values are preferred, containers with higher CDR values in this range (e.g., 4.0) will have an increased risk of delamination and should only be paired with solutions of low corrosivity. Containers with CDR values greater than 5.0 are known to con-

![Figure 1](image1.png) **Figure 1** Schematic of the major steps in the CDR test method

<table>
<thead>
<tr>
<th>Chemical Durability</th>
<th>Ratio (CDR)</th>
<th>=</th>
<th>“As-received” vial titrant volume</th>
<th>&lt;660&gt; Surface Glass Test*</th>
<th>≈</th>
<th>Etched vial titrant volume</th>
<th>&lt;660&gt; Surface Etching Test*</th>
</tr>
</thead>
</table>

*At reduced volume

![Figure 2](image2.png) **Figure 2** CDR mathematical expression
tain heterogeneities sufficient for delamination. The exact time required for the corroded regions to spill off into solution as a delaminated flake will depend upon the corrosivity of the solution.

The CDR results show vials deemed “Type I” by USP <660> and Ph. Eur. Glass containers for pharmaceutical use (3.2.1) can include a large range of chemical durability. The CDR method has been shown to quantitatively distinguish populations with known performance variation (i.e., delaminating populations). Surface characterization results confirm that vials with measured CDR values closer to 1.0 have more consistent surface chemistry (relative to the underlying surface) and are at lowest general risk for delamination. Glass manufacturers might utilize this method to understand and improve their products or implement process control. Similarly, pharmaceutical companies might employ the method during container selection (to understand relative risk and performance between container options) and during manufacturing (to monitor incoming container quality).

This new CDR method offers significant advantages for evaluating the risk of delamination compared to existing screening strategies. This screening targets the typical drug-glass contact surface with pharmacologically relevant fill volumes, samples a larger population of containers and requires less time relative to other test methods. In addition, this method can quantify differences in chemical durability when heterogeneities are present and can be easily implemented in a pharmaceutical or glass supplier laboratory.

For more information on this method, click here (pdf file).
T-Cell Therapy Saves a Life
Marilyn L. Foster, PDA

Emily Whitehead was diagnosed with standard-risk pre-b acute lymphoblastic leukemia when she was only five years old. After two rounds of chemotherapy, an infection that almost cost her both legs and a full relapse, she became Patient 1 in a Phase 1 trial of T-cell therapy.

In the opening sessions of the 2020 Virtual PDA Annual Meeting (Jul. 20 – 22), Tom G. Whitehead shared the moving story about how T-cell therapy saved his daughter’s life, and Elliot C. Norry, MD, Chief Medical Officer of Adaptimmune, described how these life-saving therapies work.

In his presentation, “Delivering T-Cells to Patients: Challenges and Successes,” Norry explained the Autologous Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell therapies his company develops for the treatment of cancer. T-cells, a group of white blood cells that help find and fight things foreign to the body like bacteria and viruses, attack and clear them using an inflammatory response. Adaptimmune has developed SPEAR T-cells that specifically recognize certain cancer cells as foreign and target them.

“Behind every bag of SPEAR T-cells manufactured,” Norry stressed, “is an individual living with cancer.” And the individual is usually a patient with an advanced form that has not responded to other treatments.

He illustrated the patient’s journey from leukapheresis to infusion and the process of engineering the SPEAR T-cells. Adaptimmune ships the modified T-cells back to a patient’s treatment center; the whole process usually takes 22-25 days. Before being infused with their SPEAR T-cells, the patient undergoes lymphodepleting chemotherapy to “make space” for the incoming cells and improve the efficacy of the treatment.

Several factors present a challenge to the process, Norry noted, starting with the fact that each product batch is unique to the patient.

The apheresis starting material and the cell dose range will vary depending on the patient’s age, health and prior treatments, meaning no two products ever look the same. As such, a strict chain of custody must be maintained, location and temperature of the cells monitored at all times, and special measures taken to ensure that patients receive only their own cells.

Aligning patient scheduling with manufacturing capability creates a need for flexible capacity, requiring Adaptimmune to maintain control of the entire process. The growing success of the treatment in several different advanced cancers is why the company continues to pursue SPEAR T-cell studies, to improve the process and increase the availability of the treatment across a broader population.
Putting T-Cells to the Test
Whitehead enthusiastically supported T-cell therapies in his presentation, “Journey to Car-T Cell Therapy,” where he detailed the steps his family took to save their daughter Emily.

Following Emily’s diagnoses, Whitehead consulted with oncologists from Pennsylvania’s Hershey Medical Center and Children’s Hospital of Philadelphia (CHOP). They started Emily on outpatient chemotherapy at Hershey as it was “only a two-hour drive instead of four.” Soon after, she awoke one night with severe pain in her legs; she had developed infection in both legs, necrotizing fasciitis. The ER doctor said they may have to amputate both legs to save her. Whitehead remarked, “We had started with hope. Now we were really scared.” Fortunately, the infection was not in the muscle, but around it, so amputation wasn’t necessary, and Emily went back to chemo.

The majority of children with ALL are cured after a two-year treatment with standard chemotherapy and, initially, that worked. But 16 months later, Emily “felt the cancer in [her] bones again.” Despite the two rounds of chemo, a bone marrow test confirmed it. Because Emily went into full relapse, she was no longer considered a “standard risk” and a bone marrow transplant was not an option. All Hershey could offer was another round of more intense chemo.

Whitehead got a second opinion from Susan Rheingold, MD, at the CHOP Cancer Center, but received the same answer, so they continued treatment at Hershey, seeking a donor for an allogeneic stem cell transplant. One was found and the transplant was scheduled for February 2012, but before then, Emily relapsed again.

Her leukemia was so aggressive this time, doctors recommended Whitehead take Emily home for hospice care. Not giving up, Whitehead applied for an experimental clinical study of CAR T-cell therapy at CHOP. The study was underway, but the therapy had never been used on children. In the meantime, Emily underwent a new chemo they knew “wouldn’t cure her but would give her some time.”

It proved to be just enough, as soon the T-cell therapy clinical trial was approved, and in April 2012, Emily became Patient 1 in the Phase 1 pediatric trial.

As the doctor explained the process to Emily, they would use her T-cells to “build an army that would fight the cancer,” and took her T-cells “off to boot camp.” With no immune system, Emily remained in isolation for six weeks. When it was time to return her strengthened army of cells, they infused her in a stepped process—10% one day, 30% the next, 60% the last—to determine what was effective and to evaluate her reaction, especially since they had no existing protocol for dosing a child. Emily withstood the first two doses well, not even showing the flu-like symptoms the family had expected, but the final dose knocked her out.

After receiving the 60% dose, Emily experienced cytokine release syndrome, a “cytokine storm” that brought on a raging fever (106°F at one point), chills, hallucinations, labored breathing and a sudden drop in blood pressure. She was put on a ventilator and induced into a coma to relieve the pain; the steroids they pumped into her to reduce pain and inflammation, instead swelled her body beyond recognition.

The doctors gave Emily a one in one-thousand chance of surviving the night, but Whitehead asked her to try to get through it, held her hand throughout the ordeal and told the doctors, “just don’t give up on her.” Emily kept fighting throughout her 14-day coma.

Whitehead said, one test revealed her interleukin-6 level was “higher than anyone alive,” 1000 times above normal. By chance, Carl H. June, MD, who led the clinical team at the University of Pennsylvan, recognized the IL-6 protein as one involved in rheumatoid arthritis, a disease that afflicted his daughter. He determined that Emily be treated with tocilizumab, the drug his daughter takes, though it had never been used in cancer patients. The results were dramatic! Within hours, her fever was down, her breathing came easier and her blood pressure normalized. She woke a week later on her seventh birthday. Twenty-three days after that, she texted her family “no cancer cells, T cells worked!” Eight years later, Emily is still cancer-free, thanks to the T-cell therapy that turned her life around.

In the Q&A that followed his presentation, Whitehead replied that Emily is now a typical 15-year-old girl who, while hanging out with her family in isolation during the pandemic, spends lots of time texting friends. As a strong supporter of T-cell therapy, Whitehead and his wife, Kari, started the Emily Whitehead Foundation to help other families navigate childhood cancer and advocate for pediatric cancer research so others can have the same positive outcome as Emily.

Asked about the future of cell therapies, Norry said, “Harnessing a patient’s own immune system to help fight cancer makes sense. I don’t know what the future looks like, but I hope it expands to help more patients even earlier in their course of therapy.”

About the Author
Marilyn Foster is PDA’s Technical Editor/Writer who works with volunteers to prepare PDA technical reports and other documents. She has more than 20 years of experience writing/editing for the pharmaceutical industry, for the Nonprescription Drug Manufacturers Assn. and the U.S. Pharmacopeia. During Covid, she has moonlighted writing articles for the PDA Letter.
PDA President Richard Johnson on the Impact of COVID-19 on the Supply Chain

**SUPPLY CHAIN ISSUES**

- Disruption of Supply Chain
- Demand Increases
- Need for Resilience
- Regulatory Response

**Drug Shortages**

- Shortages have been reported for drugs that are used to keep patients’ airways open, as well as antibiotics, antivirals and sedatives.
- Orders for broad-spectrum antibiotics like azithromycin and antiviral like ribavirin have tripled.
- Medicines for sedation and pain management like fentanyl, midazolam and propofol have been increased by 100, 70 and 60% respectively.

**Supply Chain Disruption**

- With the virus still a live threat and a number of regions and economies in lockdown, while others emerge into a very different world, the disruption to supply chains continues to be severe.
- Business leaders must make rapid decisions and take immediate actions to sustain business operations to serve their customers, clients and communities, as well as protect and support their workers.

**Supply Chain Demand**

- Initial impact was on PPE – dramatic increase in demand, impact on healthcare workers.
- Second impact – rapid development of diagnostics.
- Third impact – dramatic increase in demand for ancillary drugs needed for respiratory failure (anesthetics, antibiotics).

**Regulatory Response to the COVID-19 Outbreak**

- All major health authorities began monitoring and developing action plans early in 2020.
- Actions included: suspension of travel for inspectors.

**Drugs of 2020**

- Emergency Use Authorizations to permit importation and allow usage of products with limited data, under clinical observation.
- Publication of guidance for various pandemic related issues.
Join the Conversation on PDA CONNECT℠

The interactive, online community exclusively for you!

With PDA CONNECT℠ you can:

- Network and collaborate with fellow PDA members around the world
- Participate in discussions about niche topics in your Interest Groups
- Gain access to members-only digital resources
- Connect and engage with your local chapter

Not a PDA Member?

Join today to gain full access to PDA CONNECT℠ and more!